Sunday 18 October 2026
Export IPSC’s income statement to Excel — free account
Century Therapeutics, Inc.
IPSC Healthcare Biotechnology
Century Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $109.2 million, up 1,556.8% from fiscal 2024. In the quarter to June 2026, revenue grew 12,667.7%, EPS grew 55.3% and free cash flow grew 26.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.37
0.13
−8.67%
Follow IPSC
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (49.65%) | (42.67%) | (5.98%) | (14.23%) |
+8 more TTM periods Free account |
|
| (38.41%) | (33.57%) | (3.32%) | (8.36%) | ||
ROIC |
(64.92%) | (55.38%) | (25.79%) | (48.57%) | |
Return on Tangible Assets |
(76.15%) | (62.28%) | (6.36%) | (15.63%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.43) | (0.49) | (1.21) | (1.31) | |
Free Cash Flow |
(88.03) | (95.47) | (104.72) | (113.18) | |
Capital Expenditures |
(1.27) | (0.96) | (0.85) | (1.16) | |
| Other line items | |||||
Cash ROIC |
(25.01%) | (23.90%) | (37.93%) | (36.62%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.79 | 0.88 | 10.84 | 4.23 | |
Depreciation/Fixed assets |
0.32 | 0.23 | 0.21 | 0.18 | |
Capex/Depreciation |
(0.11) | (0.09) | (0.08) | (0.12) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.42) | (0.49) | (1.20) | (1.30) | |
Capex per Share |
(0.01) | 0.00 | (0.01) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates